ClinicalTrials.gg
Not yet recruitingNCT06024525Updated Sep 6, 2023

Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters Swide®

An interventional study of Paclitaxel-Coated Coronary Balloon Catheters and Paclitaxel-Releasing Coronary Balloon Catheters in Coronary Artery Disease, sponsored by Shanghai Shenqi Medical Technology Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by Shanghai Shenqi Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Planned enrollment
184th of 324
236 · median 307
Started
2024
with 37 others
No phase
210 of 543
71 open now
Primary completion
2025-06
later than 51 of 209 live
Registered
371st of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 184th largest by planned enrollment of the 324 interventional ones that give a count, is one of 38 that started in 2024, is one of 210 with no phase, reaches primary completion later than 51 of the 209 other live ones, and was the 371st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and efficacy of the Paclitaxel-Coated Coronary Balloon Catheters Swide® (3µg/mm2 balloon surface area) in the treatment of Chinese patients with native coronary heart disease and small vessel lesions(reference diameters from 2.0mm to 2.75 mm) in comparison with Paclitaxel-Releasing Coronary Balloon Catheter SeQuent® please Neo

Read the detailed description

This study conducted a prospective, multi-center, randomized controlled, non-inferiority clinical trial to compare the safety and efficacy of the Shenqi Medical paclitaxel-coated coronary balloon catheter and the paclitaxel-eluting coronary balloon catheter (SeQuent® please Neo) in the treatment of coronary artery small vascular disease.

  • A total of 236 participants are planned to be recruited, and they will be allocated into the experimental group and the control group in a 1:1 ratio.
  • All participants will undergo clinical follow-up at 1 month, 6 months, 9 months, 1 year, and 2 years after receiving the drug-eluting balloon angioplasty procedure.
  • Angiographic re-evaluation will be conducted for all participants at 9 months after the procedure. The primary study endpoint will be the in-segment diameter stenosis in target lesion(%) at 9 months postoperatively.
03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Related to the patients:

  1. Age ≥18 and ≤80 years old;
  2. Subjects with stable angina, or with unstable angina, or with subacute, old myocardial infarction, or evidence of asymptomatic ischemia;
  3. Subjects with ≥ 30%;
  4. During the study, women of childbearing age should not become pregnant or plan to become pregnant. Therefore, it is recommended that subjects use adequate measures until (including) the end of the follow-up period;
  5. Subjects should have sufficient compliance and agree to receive follow-ups in month-1, 6, 9 and 12, and follow-up visit in year-2. It is required to perform angiography in 9 month;
  6. Subjects should volunteer to participate in this study, and sign the written form, and understand all risks and benefits in the informed consent document.

    Related to the diseases:

  7. The target lesion is primary, in situ coronary artery lesion, located on 1 or 2 different coronary vessels, and the number of target lesions on each coronary vessel does not exceed 1;
  8. Reference vessel diameter between 2.0 mm and 2.75 mm;
  9. Non-target vascular lesions need to be treated with interventional therapy first (must be treated at the same time), after successful treatment, random and target lesions will be treated;
  10. Preoperative diameter stenosis must be ≥70% or ≥50% with ischemia; (visual inspection)
  11. Each target lesion can only be treated with one experimental drug balloon;

Exclusion criteria

Exclusion Criteria:

  1. Subjects with myocardial infarction within one week, or subjects whose troponin has not returned to normal despite the onset of myocardial infarction for more than one week;
  2. Subjects with severe congestive heart failure or IV heart failure;
  3. Women who are pregnant or breastfeeding;
  4. Subjects whose does not exceed 1 year or who have factors that make clinical follow-up difficult;
  5. Subjects with stroke within 6 months;
  6. Subjects who are participating in any other clinical trials and have not reached the primary clinical endpoint;
  7. Existing or history of severe liver failure, therefore not eligible for angiography;
  8. Existing or history of severe renal failure (\<30ml/min), therefore not eligible for angiography;
  9. Heart transplant;
  10. Cardiogenic shock;
  11. Coronary artery spasm without significant stenosis;
  12. The researchers think that the subjects are not suitable for others inclusion reason;
  13. Evidence of extensive thrombus in the target vessel before intervention;
  14. Coronary artery bypass grafting using vein grafts;
  15. Complete occlusion of the target vessel (TIMI grade 0 blood flow before operation)
  16. Target vessels are distorted or have calcified lesions that cannot be pre-dilated successfully;
  17. Lesions within 5 mm from the coronary artery ostia;
  18. Lesions that cannot be treated with PTCA or other interventional techniques;
  19. After pre-dilation of the target lesion, residual stenosis > 50% or TIMI blood flow \< grade 3, and/or type C or above dissection;
  20. Subjects with bleeding constitution, anticoagulant or antiplatelet drugs;
  21. Subjects who cannot tolerate aspirin and/or clopidogrel or have a history of neutropenia or thrombocytopenia, or severe liver insufficiency that prohibits clopidogrel;
  22. Subjects who are known to be intolerant or allergic to heparin, contrast medium, paclitaxel, iopromide, polylactic acid-glycolic acid polymer, stainless steel, etc.;
  23. Leukopenia (white blood cell count \<3×109/L for more than 3 days) or neutropenia (ANC\<1000 neutrophils/mm3 for more than 3 days) or history of thrombocytopenia (\<100,000 /mm3) subjects;
  24. Subjects with a history of peptic ulcer or gastrointestinal bleeding in the past 6 months;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    Paclitaxel-Coated Coronary Balloon Catheters

    receiving the treatment with Swide®DCB in small vessel cohort

    Device: Paclitaxel-Coated Coronary Balloon Catheters

  • Active comparator
    Paclitaxel-Releasing Coronary Balloon Catheter

    receiving the treatment with SeQuent® please Neo in small vessel cohort

    Device: Paclitaxel-Releasing Coronary Balloon Catheters

Interventions

  • DevicePaclitaxel-Coated Coronary Balloon Catheters

    to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients

  • DevicePaclitaxel-Releasing Coronary Balloon Catheters

    to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients

06

What researchers measure

Primary outcomes

  1. In-segment diameter stenosis in target lesion(%).

    DS% = (1 - minimum luminal diameter within the target lesion segment / reference diameter within the target lesion segment) × 100%.

    Time frame: 9 months

Secondary outcomes

  1. Technical success rate

    defined as the successful arrival of the device to the target lesion, successful dilation, and smooth withdrawal, without the use of any additional interventional treatment methods, with residual stenosis ≤30% (estimated method), TIMI blood flow grade 3, and no grade C or higher dissection.

    Time frame: Immediate postoperative

  2. Lesion success rate

    defined as residual stenosis within the target lesion segment being ≤30% (estimated method) after using any interventional treatment method, with TIMI blood flow grade 3 and no grade C or higher dissection.

    Time frame: Immediate postoperative

  3. Procedural success rate

    defined as the absence of device-related composite endpoint events during the hospitalization period on the basis of lesion success rate

    Time frame: during the hospitalization and no more 7 days

  4. The proportion of subjects with target lesion failure.

    defined as the composite endpoint of cardiac death, target vessel-related myocardial infarction (TV-MI) and ischemia-driven target lesion revascularization (ID-TLR);

    Time frame: in month-1, 6, 9, 12 ,24

  5. The proportion of subjects with patient-related composite endpoints

    defined as the composite endpoint of all-cause death, all myocardial infarctions, and any revascularization

    Time frame: in month-1, 6, 9, 12 ,24

  6. Proportion of Subjects' mortality

    Time frame: in month-1, 6, 9, 12 ,24

  7. Proportion of Subjects' myocardial infarction

    Time frame: in month-1, 6, 9, 12 ,24

  8. Proportion of Subjects' target lesion revascularization

    Time frame: in month-1, 6, 9, 12 ,24

  9. Proportion of Subjects' any coronary revascularization

    Time frame: in month-1, 6, 9, 12 ,24

  10. Proportion of Subjects with Thrombotic Events as defined by ARC

    includes definite, probable, and unexcluded thrombus in the acute, subacute, late, and late late timeframes

    Time frame: in month-1, 6, 9, 12 ,24

  11. Incidence Rate of All AE and SAE in subjects

    Time frame: in month-1, 6, 9, 12 ,24

  12. Late Lumen Loss

    defined as the change in minimal lumen diameter

    Time frame: 9 months

  13. Incidence of target lesion restenosis

    proportion of patients with \>50% diameter stenosis

    Time frame: 9 months

07

Study locations

1 site
  • Meizhou People's Hospital (Huangtang Hospital, Meizhou Academy of Medical Sciences)
    Meizhou, Guangdong, China
    • ZHIXIONG ZHONG · Contact+86 753 213 1363
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Jun 2025, 17 months later.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 17 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2023
First posted
Sep 6, 2023
StartEst.
Jan 1, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2026
Last update
Sep 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06024525
Lead sponsor
Shanghai Shenqi Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Jan 1, 2024 (estimated)
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Sep 6, 2023

Study contacts

chaojun gu
Contact
chaojun.gu@sqmedical.com
+86-13636491192

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion